Clinical trial
Intensified Post Remission Therapy Containing PEG-Asparaginase
NCT00184041 · University of Southern California, Other · Completed
Key facts
| NCT number | NCT00184041 |
|---|---|
| Title | Intensified Post Remission Therapy Containing PEG-Asparaginase |
| Official title | Treatment Of Newly Diagnosed Adult Acute Lymphoblastic Leukemia With Intensified Post Remission Therapy Containing PEG-Asparaginase. |
| Lead sponsor | University of Southern California, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Lymphoblastic Leukemia |
| Intervention type | Drug |
| Interventions | Daunorubicin, Vincristine, Prednisone, Methotrexate, PEG-Asparaginase, 6-Mercaptopurine, Cytoxan, Cytosine Arabinoside, VM-26 and 6-Thioguanine |
| Enrollment | 47 |
| Start date | Jul 1, 2004 |
| Primary completion | Dec 1, 2011 |
| Completion | Dec 1, 2012 |
| First posted | Sep 16, 2005 |
| Last update posted | May 22, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: